BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence.

By Mingzhao Xing, Rengyun Liu, Xiaoli Liu, A. K. Murugan, Guangwu Zhu, M. Zeiger, S. Pai, J. Bishop. Journal of Clinical Oncology, 2014

650 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/cb2f7f69eb18567feb7aa29255b0f5a387ba6f68

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Y. Nikiforov

In Surgery

1. Y. Nikiforov
2. Eric S. Lander

Citations in the corpus

• Overview of the 2022 WHO Classification of Thyroid Neoplasms (2022, background): “Indeed, telomerase reverse transcriptase (TERT) promoter mutations have been found to predict worse clinical outcome in PTC patients with synchronous BRAF mutations, suggesting a synergic effect [169, 170].”
• Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014, background): “Similarly, TERT promoter mutations identified a subset of aggressive, less-differentiated PTCs, consistent with recent reports (Melo et al., 2014; Xing et al., 2014).”
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, positive): “Furthermore, the combination of a TERT mutation and a BRAF mutation within the same tumor was associated with a high risk of structural disease recurrence (155).”